RS60186B1 - Indukcija malog molekula trail genom u normalnim i tumorskim ćelijama kao antikancerska terapija - Google Patents

Indukcija malog molekula trail genom u normalnim i tumorskim ćelijama kao antikancerska terapija

Info

Publication number
RS60186B1
RS60186B1 RS20200454A RSP20200454A RS60186B1 RS 60186 B1 RS60186 B1 RS 60186B1 RS 20200454 A RS20200454 A RS 20200454A RS P20200454 A RSP20200454 A RS P20200454A RS 60186 B1 RS60186 B1 RS 60186B1
Authority
RS
Serbia
Prior art keywords
normal
tumor cells
small molecule
anticancer therapy
gene induction
Prior art date
Application number
RS20200454A
Other languages
English (en)
Inventor
Wafik S El-Deiry
Joshua E Allen
Gen Sheng Wu
Original Assignee
Penn State Res Found
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Penn State Res Found filed Critical Penn State Res Found
Publication of RS60186B1 publication Critical patent/RS60186B1/sr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4188—1,3-Diazoles condensed with other heterocyclic ring systems, e.g. biotin, sorbinil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
RS20200454A 2011-04-29 2012-04-30 Indukcija malog molekula trail genom u normalnim i tumorskim ćelijama kao antikancerska terapija RS60186B1 (sr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161480743P 2011-04-29 2011-04-29
EP12776073.4A EP2701708B1 (en) 2011-04-29 2012-04-30 Small molecule trail gene induction by normal and tumor cells as an anticancer therapy
PCT/US2012/035831 WO2012149546A2 (en) 2011-04-29 2012-04-30 Small molecule trail gene induction by normal and tumor cells as an anticancer therapy

Publications (1)

Publication Number Publication Date
RS60186B1 true RS60186B1 (sr) 2020-06-30

Family

ID=47068061

Family Applications (1)

Application Number Title Priority Date Filing Date
RS20200454A RS60186B1 (sr) 2011-04-29 2012-04-30 Indukcija malog molekula trail genom u normalnim i tumorskim ćelijama kao antikancerska terapija

Country Status (16)

Country Link
US (8) US8673923B2 (sr)
EP (3) EP3679934A1 (sr)
JP (6) JP6132833B2 (sr)
CA (1) CA2832342C (sr)
CY (1) CY1123010T1 (sr)
DK (1) DK2701708T3 (sr)
ES (1) ES2786033T3 (sr)
HR (1) HRP20200636T1 (sr)
HU (1) HUE049207T2 (sr)
LT (1) LT2701708T (sr)
MX (2) MX365365B (sr)
PL (1) PL2701708T3 (sr)
PT (1) PT2701708T (sr)
RS (1) RS60186B1 (sr)
SI (1) SI2701708T1 (sr)
WO (1) WO2012149546A2 (sr)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012149546A2 (en) 2011-04-29 2012-11-01 The Penn State Research Foundation Small molecule trail gene induction by normal and tumor cells as an anticancer therapy
US10813630B2 (en) 2011-08-09 2020-10-27 Corquest Medical, Inc. Closure system for atrial wall
US10307167B2 (en) 2012-12-14 2019-06-04 Corquest Medical, Inc. Assembly and method for left atrial appendage occlusion
US10314594B2 (en) 2012-12-14 2019-06-11 Corquest Medical, Inc. Assembly and method for left atrial appendage occlusion
US20140142689A1 (en) 2012-11-21 2014-05-22 Didier De Canniere Device and method of treating heart valve malfunction
HUE044238T2 (hu) * 2013-03-13 2019-10-28 Oncoceutics Inc 7-benzil-10-(2-metilbenzil)-2,6,7,8,9,10-hexahidroimidazo[l,2-a]pirido[4,3-d]pirimidin-5(3h)-on rák kezelésénél történõ alkalmazásra
US9376437B2 (en) 2013-03-13 2016-06-28 Oncoceutics, Inc 7-benzyl-4-(2-methylbenzyl)-2,4,6,7,8,9-hexahydroimidazo[1,2-a]pyrido[3,4-e]pyrimidin-5(1H)-one, salts thereof and methods of using the same in combination therapy
WO2015073072A1 (en) * 2013-11-15 2015-05-21 Oncoceutics, Inc. 7-benzyl-4-(2-methylbenzyl)-2,4,6,7,8,9-hexahydroimidazo[1,2-a]pyrido[3,4-e]pyrimidin-5(1h)-one
US9688679B2 (en) 2013-03-13 2017-06-27 Oncoceutics, Inc. 7-benzyl-4-(methylbenzyl)-2,4,6,7,8,9-hexahydroimidazo[1,2-A]pyrido[3,4-E]pyrimidin-5 (1H)-one, salts thereof and methods of using the same in combination therapy
DK3546461T3 (da) * 2013-11-15 2021-09-13 Oncoceutics Inc 7-benzyl-4-(2-methylbenzyl)-2,4,6,7,8,9-hexahydroimidazo[1,2-a]pyrido[3,4-e]pyrimidin-5(1h)-one, salts thereof and methods of using the same in combination therapy
US9566443B2 (en) 2013-11-26 2017-02-14 Corquest Medical, Inc. System for treating heart valve malfunction including mitral regurgitation
WO2015138638A1 (en) 2014-03-11 2015-09-17 Theraly Pharmaceuticals, Inc. Long acting trail receptor agonists for treatment of autoimmune diseases
RS60163B1 (sr) 2014-03-31 2020-05-29 Scripps Research Inst Farmakofor koji indukuje trail
US10842626B2 (en) 2014-12-09 2020-11-24 Didier De Canniere Intracardiac device to correct mitral regurgitation
MX2017009841A (es) 2015-01-30 2018-02-09 Oncoceutics Inc 7-bencil-4-(2-metilbencilo) -2,4,6,7,8,9-hexahidroimidazo [1,2-a] pirido [3,4-e] pirimidin-5 (1h) -ona, analogos y sales del mismo y su uso en terapia.
WO2016160918A1 (en) 2015-03-31 2016-10-06 The University Of North Carolina At Chapel Hill Delivery vehicles for stem cells and uses thereof
CN104860948B (zh) * 2015-05-15 2017-09-26 南京盖特医药技术有限公司 咪唑并嘧啶酮类化合物及其制备方法和应用
WO2017106627A1 (en) 2015-12-17 2017-06-22 The Johns Hopkins University Ameliorating systemic sclerosis with death receptor agonists
NZ745425A (en) 2016-01-29 2023-03-31 Oncoceutics Inc G protein-coupled receptor (gpcr) modulation by imipridones
WO2017177148A1 (en) 2016-04-07 2017-10-12 The Johns Hopkins University Compositions and methods for treating pancreatitis and pain with death receptor agonists
US10172862B2 (en) 2017-01-30 2019-01-08 Oncoceutics, Inc. Imipridones for gliomas
US11767353B2 (en) 2020-06-05 2023-09-26 Theraly Fibrosis, Inc. Trail compositions with reduced immunogenicity

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA105008A (en) 1907-02-06 1907-04-30 Charles B. Grimshaw Self-closing valve
DE2150062A1 (de) 1971-10-07 1973-04-12 Boehringer Sohn Ingelheim Imidazo- eckige klammer auf 1,2-a eckige klammer zu -pyrido- eckige klammer auf 4,3-d eckige klammer zu -pyrimidine, deren saeureadditionssalze und verfahren zu deren herstellung
GB9407386D0 (en) 1994-04-14 1994-06-08 Smithkline Beecham Plc Pharmaceutical formulation
US5648097A (en) 1995-10-04 1997-07-15 Biotek, Inc. Calcium mineral-based microparticles and method for the production thereof
US6391336B1 (en) 1997-09-22 2002-05-21 Royer Biomedical, Inc. Inorganic-polymer complexes for the controlled release of compounds including medicinals
ES2357225T3 (es) 2001-11-01 2011-04-20 Uab Research Foundation Combinaciones de anticuerpos anti-dr5 y anticuerpos anti-dr4 y otros agentes terapéuticos.
AU2002367172A1 (en) 2001-12-21 2003-07-15 Bayer Pharmaceuticals Corporation 2,4-diamino-pyrimidine derivative compounds as inhibitors of prolylpeptidase, inducers of apoptosis and cancer treatment agents
RU2008129028A (ru) * 2005-12-16 2010-01-27 Дженентек, Инк. (Us) Способ диагностики, прогнозировния и лечения глиомы
US8084027B2 (en) * 2006-02-10 2011-12-27 Nerviano Medical Sciences S.R.L. Combinations comprising a CDK inhibitor and a growth factor antibody or anti-mitotic
EP2037919A2 (en) 2006-06-30 2009-03-25 Schering Corporation Method of using substituted piperidines that increase p53 activity
CN102105148B (zh) * 2008-07-24 2013-04-10 内尔维阿诺医学科学有限公司 包含aurora激酶抑制剂和抗肿瘤药的治疗组合
EP2349323A2 (en) * 2009-06-24 2011-08-03 Stephen Evans-Freke Methods of using corticotropin-releasing factor for the treatment of cancer
WO2012149546A2 (en) 2011-04-29 2012-11-01 The Penn State Research Foundation Small molecule trail gene induction by normal and tumor cells as an anticancer therapy
HUE044238T2 (hu) 2013-03-13 2019-10-28 Oncoceutics Inc 7-benzil-10-(2-metilbenzil)-2,6,7,8,9,10-hexahidroimidazo[l,2-a]pirido[4,3-d]pirimidin-5(3h)-on rák kezelésénél történõ alkalmazásra

Also Published As

Publication number Publication date
CA2832342A1 (en) 2012-11-01
US20170000790A1 (en) 2017-01-05
HRP20200636T1 (hr) 2020-07-10
US20150265619A1 (en) 2015-09-24
ES2786033T3 (es) 2020-10-08
JP2019019145A (ja) 2019-02-07
JP6132833B2 (ja) 2017-05-24
US9061032B2 (en) 2015-06-23
EP4335511A3 (en) 2024-05-15
US20220288079A1 (en) 2022-09-15
JP2024051080A (ja) 2024-04-10
SI2701708T1 (sl) 2020-07-31
US20120276088A1 (en) 2012-11-01
CY1123010T1 (el) 2021-10-29
US20170224690A1 (en) 2017-08-10
MX2019006379A (es) 2019-09-04
CA2832342C (en) 2019-12-31
WO2012149546A3 (en) 2013-01-03
LT2701708T (lt) 2020-05-25
US20150202206A1 (en) 2015-07-23
WO2012149546A2 (en) 2012-11-01
PT2701708T (pt) 2020-05-08
US20140248264A1 (en) 2014-09-04
EP2701708B1 (en) 2020-01-22
JP2014514326A (ja) 2014-06-19
US9629842B2 (en) 2017-04-25
US9072744B1 (en) 2015-07-07
MX2013012346A (es) 2014-08-22
US8673923B2 (en) 2014-03-18
JP2023060196A (ja) 2023-04-27
JP2016199580A (ja) 2016-12-01
US9452165B2 (en) 2016-09-27
MX365365B (es) 2019-05-30
EP2701708A4 (en) 2015-01-07
DK2701708T3 (da) 2020-04-27
EP4335511A2 (en) 2024-03-13
JP2021185210A (ja) 2021-12-09
PL2701708T3 (pl) 2020-11-02
USRE46290E1 (en) 2017-01-31
HUE049207T2 (hu) 2020-09-28
EP3679934A1 (en) 2020-07-15
EP2701708A2 (en) 2014-03-05

Similar Documents

Publication Publication Date Title
EP2701708A4 (en) INDUCTION OF THE TRAIL GENE BY SMALL MOLECULE BY NORMAL AND TUMOR CELLS AS ANTICANCER THERAPY
HK1254799A1 (zh) 使用經操作的nkt細胞靶向腫瘤微環境
HK1206782A1 (en) Widespread gene delivery of gene therapy vectors
IL231171A0 (en) RNA-derived t cells for cancer treatment
IL229649A0 (en) Dual direction
EP2683643A4 (en) PROSTATE CANCER CELL LINES, GENE SIGNATURES AND USES THEREOF
SG10201510009YA (en) Methods of metabolic targeting cancer cells using chemo- and immunotherapy for treating cancer
EP2836501A4 (en) RNA APTAMERS FOR THERAPEUTIC AND DIAGNOSTIC ADMINISTRATION ON PANCREAS CRAB CELLS
EP2908830A4 (en) CANCER THERAPY WITH MIRNAS
PL2831110T3 (pl) Terapia anty-EMP2 zmniejsza ilość rakowych komórek macierzystych
EP2885428A4 (en) GENE EXPRESSION PROFILE ASSOCIATED WITH PROSTATE CANCER
EP2691510A4 (en) METABOLISM DIRECTIONS BY TRANSCRIPTION FACTOR OVEREXPRESSION
EP2585115A4 (en) ANTICANCER TREATMENT
EP2882869A4 (en) PROSTATE CANCER GENE EXPRESSION PROFILES
EP2785870A4 (en) SMYD2 AS A TARGET GENE FOR ANTICANCER THERAPY AND THE DIAGNOSIS OF CANCER
EP2536741A4 (en) THERAPY TARGETING FUSIONS OF GENES
IL230987A0 (en) Targeted liposomes for cancer treatment
GB201106630D0 (en) Cancer therapy
GB201009217D0 (en) Targeted gene therapy
AU2012904570A0 (en) Cancer therapy using miRNAs
IL229242A0 (en) Allogeneic cell vaccine for cancer
AU2012905122A0 (en) Combination therapy by lysosomal targeting
HK1151941A2 (en) Magnetic therapy bear set
GB201020513D0 (en) Cancer therapy
GB201120096D0 (en) Novel therapy